Regeneron Pharmaceuticals

This Phase 2 trial tests an experimental drug called REGN7999 in about 95 people with non-transfusion dependent beta-thalassemia who have too much iron in their bodies. The drug is given as a shot under the skin and aims to safely reduce iron levels in the liver. Researchers will…

This study tests dupilumab, an injectable drug already used for allergies, in 22 adults and teens with eosinophilic gastritis (stomach inflammation caused by too many white blood cells). The goal is to see if it reduces inflammation and improves symptoms over 6 months to a year. …

This early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to …

This study tests a new drug, olatorepatide, for weight loss in people who are overweight or obese but do not have diabetes. The drug works by targeting hormones that control appetite and blood sugar. Researchers will check how safe the drug is, how the body processes it, and how …

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or wi…

This study tests a drug called vonsetamig in 43 people with chronic kidney disease who are on dialysis and have very high levels of anti-HLA antibodies, making it nearly impossible to find a matching kidney donor. The drug aims to safely lower these antibodies so that a kidney tr…

This study looks at the long-term safety of dupilumab (Dupixent) in children aged 6 months to 18 years with atopic dermatitis (eczema). About 880 kids who were in earlier dupilumab studies will continue treatment. Researchers will track side effects and check if a pre-filled pen …

This phase 2 trial tests whether adding an experimental immunotherapy (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combo alone for people with early-stage lung cancer that can be removed by surgery. About 195 participants will…

This study tests whether adding the injectable drug dupilumab (Dupixent) to a medium-dose inhaler works better than simply increasing the inhaler dose for people whose asthma is still not under control. About 120 adults with uncontrolled asthma will be randomly assigned to one of…

This study tests an experimental drug, odronextamab, in people with aggressive B-cell non-Hodgkin lymphoma that has come back or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiveness, and qual…

This Phase 2 trial tests two experimental drugs, trevogrumab and garetosmab, added to the weight-loss drug semaglutide (Wegovy) in about 1,000 people with obesity. The goal is to see if the combination improves weight loss and body composition (more fat loss, less muscle loss) co…

This phase 2 trial tests whether adding an mRNA vaccine (BNT116) to standard immunotherapy (cemiplimab) works better than immunotherapy alone for people with advanced non-small cell lung cancer. About 51 patients whose tumors have high PD-L1 levels will receive either the combina…

This study tests a combination of two experimental drugs, pozelimab and cemdisiran, for people with PNH, a rare blood disease that destroys red blood cells. The goal is to see if this combo works better and is safer than current standard treatments (ravulizumab and eculizumab). A…

This phase 3 trial tests whether combining two immunotherapy drugs, fianlimab and cemiplimab, works better than the standard drug pembrolizumab for people with advanced melanoma that cannot be surgically removed. About 1,500 adults and adolescents who have not had prior treatment…

This study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is …

This Phase 2 study tests an investigational drug called linvoseltamab in 40 people with high-risk smoldering multiple myeloma, a condition that often leads to active multiple myeloma. The goal is to see if the drug can safely eliminate abnormal plasma cells and prevent the diseas…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This study tests the safety of switching from the current drug metreleptin to a new experimental drug called mibavademab in people with generalized lipodystrophy, a rare condition where the body cannot properly store fat. Nine participants who have been stable on metreleptin will…

This Phase 3 trial tests whether adding the drug cemiplimab (Libtayo) after surgery and radiation helps prevent high-risk cutaneous squamous cell carcinoma from returning. About 415 participants receive either cemiplimab or a placebo intravenously every 3 weeks. The study compare…

This early-stage study tests an experimental drug called ALN-ANG3 in healthy adults with high cholesterol and triglycerides. The main goal is to check safety and side effects, not yet to see if it works. About 59 participants will receive either the drug or a placebo, and researc…

This early-stage study tests the safety of cemiplimab, a drug that helps the immune system fight cancer, alone or with other drugs in Japanese patients with advanced malignancies, especially lung cancer. About 146 participants will receive different combinations to see if tumors …

This study tests two experimental drugs, pozelimab and cemdisiran, alone or together, in 288 adults with generalized myasthenia gravis (gMG), a disease that causes muscle weakness and fatigue. The goal is to see if the drugs improve daily activities and muscle strength. Participa…

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone for people with high-risk, removable melanoma. About 151 participants will receive the drugs before surgery, then continue after. The goal is to see if the combination des…

This study tests a new drug, odronextamab, combined with chemotherapy for people with untreated follicular lymphoma, a type of blood cancer. It compares this new combo to the standard treatment (rituximab plus chemo) to see which works better. About 733 adults will take part, and…

This study tests whether adding fianlimab to the standard immunotherapy cemiplimab helps people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 850 patients will receive either the drug combo or cemiplimab alone. Researchers will mea…

This study tests whether adding fianlimab to standard immunotherapy (cemiplimab) and chemotherapy improves outcomes for people with advanced non-small cell lung cancer. About 950 participants will receive either the triple combination or the double combination. The goal is to see…

This study tests an experimental drug, garetosmab, in 63 adults with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug safely reduces new bone growth and painful flare-ups. Participants receive either t…

This program offers vidutolimod (CMP-001) to people with refractory melanoma who have run out of standard options. It is a compassionate use access, not a clinical trial, so it is only available when no other treatments are left. The goal is to provide a potential therapy for tho…

This program offers garetosmab to adults with fibrodysplasia ossificans progressiva (FOP) who finished the main OPTIMA study. The goal is to provide the drug before it is officially approved. Participants must meet specific health criteria to join.

This study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study …

This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not h…

This study provides compassionate access to pozelimab for people with CD55-deficient protein-losing enteropathy, a rare condition where the gut leaks proteins. The goal is to offer an experimental treatment option when no other therapies are available. Participants receive the dr…

This program gives patients with CHAPLE disease, a rare and life-threatening immune disorder that causes protein loss from the gut, access to the experimental drug pozelimab. The goal is to provide treatment and monitor long-term safety. Participants must have a confirmed genetic…

This program provides linvoseltamab (REGN5458) to patients with relapsed or refractory multiple myeloma who have exhausted all standard treatments. The drug is a type of immunotherapy that helps the immune system attack cancer cells. It is given through compassionate use, meaning…

This program provides evinacumab to children with homozygous familial hypercholesterolemia (HoFH) or severe high triglycerides when standard treatments don't work. The drug helps lower dangerous fat levels in the blood, but patients must keep taking it long-term to control their …

This program offers continued access to a combination of two drugs, pozelimab and cemdisiran, for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare condition where red blood cells break apart. It is for patients who have already completed a related study and aims to m…

This study tests a higher dose of the drug aflibercept (8 mg) given as an eye injection every 4 weeks to people with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME). The goal is to see if this dosing schedule is safe and works well for those who have a…

This Phase 2 trial tests an investigational drug called odronextamab in 515 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The main goal is to see if it shrinks tumors a…

This program provides compassionate use of dupilumab (Dupixent) for patients with severe type 2 inflammatory disorders who have no other treatment options. It aims to offer access to this drug outside of a clinical trial. The program is already approved for marketing.

This study was designed to test an experimental drug called garetosmab in otherwise healthy men and postmenopausal women with obesity. The goal was to check the drug's safety and how it affects hormones and blood clotting. However, the study was withdrawn before any participants …

This study tests a single dose of an experimental drug called REGN7544 in 82 people with Postural Orthostatic Tachycardia Syndrome (POTS). The goal is to see if the drug safely reduces the rapid heart rate that happens when standing up. Researchers will also check for side effect…

This study follows 48 people with advanced melanoma who previously received the experimental drugs fianlimab and cemiplimab in an earlier study. No new treatment is given; instead, researchers track their health, cancer status, and any late side effects over time. The goal is to …

This study will look back at medical records of about 1,000 people in the US with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy as their first treatment. Researchers want to see how well the treatment works and what side ef…

This study follows about 100 premature babies who were treated for retinopathy of prematurity (ROP) in an earlier study. Researchers will check their eyesight and overall development over time to see how they are doing. No new treatment is given in this study.

This study follows 11 males with Hemophilia B who already receive regular factor IX therapy to prevent bleeding. Researchers will collect information on bleeding events, treatment use, and quality of life over at least 6 months. No experimental treatment is given; the goal is to …

This early-stage study tests the safety of an experimental drug, ALN-F1202, in 56 healthy adults. The drug aims to lower a clotting factor, but this trial only checks for side effects and how the body processes the drug. Participants receive a single dose and are monitored closel…

This study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice…